ASX ANNOUNCEMENT

EXTENSION OF WONDFO SARS-CoV-2 RAPID TEST DISTRIBUTION AGREEMENT

SYDNEY, Thursday, 2 July 2020: Cellmid Limited (ASX: CDY) is pleased to advise that Guangzhou Wondfo Biotech Co., Ltd. (Wondfo) has extended its authorisation for Australia Application Pty Ltd (Australia Application) to be a distributor of the Wondfo SARS-CoV-2 antibody test in Australia (Wondfo Test) until 30 December 2020.

Cellmid and Australia Application have also amended their agreement (Agreement) for Cellmid to be a distributor of the Wondfo test in Australia such that the Agreement now also runs until 30 December 2020 and previous minimum order requirements have been removed. The amended Agreement is subject to Cellmid maintaining registration of the product with the Australian Therapeutic Goods Administration. Both the agreements between Wondfo and Australia Application and Australia Application and Cellmid may be extended beyond 30 December 2020 with written consent.

In the coming months, as the pandemic progresses, it is Cellmid's opinion that serological testing, including rapid tests, is expected to have an important role in widespread population surveys, in research and development activities such as drug and vaccine trials and as an adjunct device in diagnostic and triage settings. Recent peer reviewed article by the Doherty Institute in *Nature Medicine* also draws attention to the utility of antibody tests in clinical management of COVID-19 patients[1]

In countries where the incidence of the disease has been significantly higher, such as Spain, Germany and the United States, population wide seroprevalence studies have already commenced. With the extension of the agreements Cellmid is pleased to have maintained its ability to participate in this important potential market.

SARS-CoV-2 ANTIBODY TESTING MARKET

At the time of negotiating and signing the original supply agreement with Australia Applications in March, around the time the pandemic was declared by the World Health Organization, there was uncertainty around the manifestation of the pandemic. In anticipation of a serious outbreak, such as the one experienced in China and Europe earlier, Australian government departments and major corporations sought urgent solutions to expand their mass testing capabilities.

[1] Breadth of concomitant immune responses prior to patient recovery, Thevarajan, et al.,2020, Nature Medicine

Having secured the supply of the Wondfo Test, which was developed in China as an adjunct to the diagnosis of symptomatic individuals, Cellmid received expressions of interests for a large number of tests and participated in tenders to supply federal and some state governments, resource companies and aged care service providers, amongst others, in April 2020. As the pandemic developed in Australia during the months of May and June 2020, it has become evident that the measures implemented by the Federal and state governments have been successful and the number of COVID-19 cases remained remarkably low, even accounting for the recent outbreak in Victoria.

Concurrently, pathology groups in March negotiated an increase in government reimbursement for COVID-19 polymerase chain reaction (PCR) based testing from $24 to around $100 per test, following which PCR testing became readily available in Australia. Demand for testing in the acute phase of the disease, both PCR and antibody based, so far turned out to be much lower than expected in Australia.

The Wondfo Test is manufactured in China by Guangzhou Wondfo Biotech Co Ltd. It was recently tested by the Doherty Institute, on behalf of the TGA, and in the most relevant period of 14+ days following the onset of symptoms was shown to have the equal highest sensitivity of the tests reviewed so far (see ASX announcement 15 June 2020). Clinical validation studies have also been completed for the Wondfo Test by the manufacturer according to *Administrative Measures for Registration of In-vitro Diagnostic Reagents* by the Chinese Food and Drug Administration (see ASX announcement 27 March 2020), reporting sensitivity in the most relevant period of 14+ days following the onset of symptoms consistent with those achieved in the Doherty Institute review.

Cellmid has previously advised the market that it has broadened the SARS-CoV-2 diagnostic product range it can offer to its customers by making introductions to Emergence Technology Pty Ltd which has arrangements to supply both antibody and nucleotide tests (see ASX announcement 4 June 2020). The Wondfo Test is an important component of this suite of tests.

Approved for release by the Board of Directors.

End

Contact:
Maria Halasz, CEO
T +612 9221 6830
@mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with a consumer health business and biotech assets in development. Advangen is Cellmid's wholly owned subsidiary engaged in the development and sale of first in class, best in class, clinically validated anti-aging products for hair, skin and body. For further information, please see www.cellmid.com.au and www.evolisproducts.com.au. Cellmid's wholly owned subsidiary, Lyramid, develops innovative novel therapies and diagnostic tests for age related diseases including inflammatory and autoimmune conditions. Most recently Cellmid secured the rights to distribute the Wondfo Test in Australia and entered into an agreement to make introductions to Emergence Technology Pty Ltd which has arrangements to supply PCR and antibody point of care and laboratory based SARS-CoV-2 tests.

Forward looking statements

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as the availability of resources, regulatory environment, the results of marketing and sales activities and competition.